Key result
In children with central idiopathic precocious puberty, GnRH agonist treatment sustained high IGFBP-3 levels despite reduced GH secretion, with a significant positive correlation between IGFBP-3 and GHBP activity.
Why the study?
Does leuprolide acetate alter IGFBP-3 and GHBP levels in children with central idiopathic precocious puberty?
Observational (n=8)
Yes
Does leuprolide acetate alter IGFBP-3 and GHBP levels in children with central idiopathic precocious puberty?
In children with central idiopathic precocious puberty, suppression of gonadal steroids with a GnRH agonist results in sustained high levels of IGFBP-3, which may interfere with the growth-promoting effect of IGF-I.
Answers are grounded in this paper and cite their sources.
May blunt growth response to IGF-I during GnRHa therapy in CPP; hypothesis-generating and requires larger prospective confirmation.
The direct role of sex steroids in pubertal bone growth may be an increased growth hormone (GH) receptor-coupled GH action. We previously reported that suppression of sex steroids by a gonadotropin-releasing hormone (GnRH) agonist (leuprolide acetate) increases the activity of serum growth hormone-binding protein (GHBP), identical to the extracellular domain of GH receptor, in central idiopathic precocious puberty (CIPP). Since insulin-like growth factor (IGF) -binding protein 3 (IGFBP-3) is a GH-dependent IGF binding protein, we measured IGFBP-3 and GHBP before and after treatment with the GnRH agonist in eight children with CIPP. IGFBP-3 and GHBP were measured by radioimmunoassay and immunoprecipitation.The treatment suppressed gonadal function. The initial IGFBP-3 level was high. After the treatment, IGFBP-3 remained at this level despite a reduction in GH secretion. There was a significant positive correlation between IGFBP-3 level and GHBP activity (r=0.63, p<0.01).The high IGFBP-3 level in a patient with CIPP is presumed to result from increased GH secretion, similar to the GH-dependent increase in IGF-I. Although we can not explain the sustained increase in IGFBP-3 after gonadal suppression, the high IGFBP-3 level may interfere with the growth promoting effect of IGF-I.
No takes yet. Share an insight, caveat, or question.
Murata et al. (1994) conducted an observational in Central idiopathic precocious puberty (CIPP) (n=8). GnRH agonist (leuprolide acetate) vs. Baseline (pre-treatment) was evaluated on Correlation between IGFBP-3 level and GHBP activity (r=0.63, p=<0.01). In children with central idiopathic precocious puberty, GnRH agonist treatment sustained high IGFBP-3 levels despite reduced GH secretion, with a significant positive correlation between IGFBP-3 and GHBP activity.
Synapse has enriched 10 related papers. Consider them for comparative context: